We investigated whether administration of estradiol to male mice augments mobilization of bone marrow-derived endothelial progenitor cells (EPC) and incorporation into foci of neovascularization after hind-limb ischemia, thereby contributing to blood flow restoration. Mice were randomized and implanted with placebo pellets or pellets containing low-dose estradiol (0.39 mg) or high-dose estradiol (1.7 mg). Hind-limb ischemia was induced by unilateral resection of the left femoral artery 1 week after pellet implantation, then EPC mobilization and functional recovery was evaluated. EPC recruitment was assessed in mice transplanted with bone marrow from transgenic donors expressing β-galactosidase driven by the Tie-2 promoter. EPC culture assay performed 2 weeks after pellet implantation revealed a significantly greater (p < 0.05) number of circulating EPCs in the high-dose estradiol group than in the low-dose estradiol and placebo groups. At 3 and 4 weeks after induction of hindlimb ischemia, perfusion was significantly greater (p < 0.05) in high-dose estradiol mice than in mice implanted with the low-dose estradiol or placebo pellets. At 1 and 4 weeks after hind-limb ischemia surgery, more bone marrow-derived EPCs, identified as β-galactosidase-positive cells, were observed in ischemic regions from highdose estradiol animals than in low-dose (p < 0.05) or placebo groups (p < 0.05). These results indicate that estradiol dose-dependently increases the levels of EPCs in peripheral blood in male animals, improves the recovery of blood flow, and decreases limb necrosis after hind-limb ischemia, and that this enhancement occurs, in part, through augmentation of EPC mobilization and greater incorporation of bone marrow-derived EPCs into foci of neovascularization.
Introduction
Since the discovery of endothelial progenitor cells (EPCs) in 1997, 1 many studies have investigated their potential angiogenic capacity. [2] [3] [4] [5] [6] The relationships between EPCs and various growth factors, cytokines, and hormones, including estrogen, 7 have been studied in an effort to identify their potential for therapeutic angiogenesis. The emerging consensus of these studies is that blood-vessel regen-eration evolves not only from the migration and proliferation of endothelial cells adjacent to the site of injury (a process called angiogenesis), but that circulating EPCs also contribute to the formation of new blood vessels. 1, [8] [9] [10] The mechanisms that regulate EPC-mediated neovascularization are slowly being characterized. 5, 11, 12 Estrogen regulates angiogenesis by influencing the activity of endothelial cells. Under normal physiological conditions, angiogenesis in the uterus is associated with fluctuations of circulating estradiol (E2) and other sex steroids. [13] [14] [15] [16] [17] The wellestablished link between estrogen and breast tumor invasiveness also suggests that estrogen exerts a proangiogenic effect because the formation of metastases is dependent on angiogenesis. 18 Studies in mice have revealed that E2 accelerates endothelial recovery after arterial injury, 19, 20 and E2 has been shown to prevent endothelial cell apoptosis 5, 21, 22 and to exert other positive effects on mature endothelial cells.
To date, experiments in animal models that have investigated the effects of E2 on EPCs have been performed exclusively in female animals, 5, 12, 22 and it is not known whether these results can be extrapolated to males. Furthermore, the potential contribution of EPC-mediated neovascularization to functional recovery at the ischemic site continues to be debated. This study sought to determine whether estrogen mobilizes EPCs from the bone marrow after hind-limb ischemia (HLI) in male animals, and whether the mobilized EPCs subsequently contribute to post-ischemic neovascularization.
Methods

Animal models
All experiments were conducted according to protocols approved by the Animal Care and Use Committee of St Elizabeth's Medical Center, Boston, MA and conform to the Guide for the Care and Use of Laboratory Animals by the US National Institutes of Health. Experiments were performed in male FVB wild type (WT) mice (Jackson Laboratory, Bar Harbor, ME, USA), aged 6 weeks. HLI was induced by unilateral resection of the left femoral artery from the proximal end of the femoral artery up to the distal portion of the saphenous vein. The femoral artery and all side-branches were dissected and excised, then the overlying skin was closed using a surgical stapler. After surgery, the mice were kept on a warm plate until fully awake. For bone marrow transplant experiments, mice were irradiated (16 G) to destroy endogenous bone marrow and transplanted with a minimum of 3 × 10 6 bone marrow cells from age-matched male transgenic donors that expressed β-galactosidase; β-galactosidase transcription was regulated by the endothelial cell-specific Tie-2 promoter. Mice were anesthetized by intraperitoneal injection with a mixture of ketamine (80 mg/kg) and xylazine (4 mg/kg) and sacrificed with an overdose of the same anesthetic. Animals were housed under standard conditions with ad libitum food and water. Over the duration of the experiments, the mortality rate was 6% for intact mice, 10% for mice that underwent HLI surgery alone, and 33% for mice that underwent both bone marrow transplantation and HLI surgery.
Design
Three experiments were performed. For each experiment, non-castrated WT male mice were implanted with 90-day release E2 pellets containing high (1.7 mg/pellet) or low (0.39 mg/pellet) doses of E2 (17β-estradiol), or placebo (Innovative Research of America, Sarasota, FL, USA). In a previous study of experimental carotid artery injury, serum E2 levels were approximately 300-fold greater in ovariectomized female mice implanted with the highdose E2 pellet than in mice implanted with the placebo pellet. 5 Pellets were implanted subcutaneously as described elsewhere. 12 The first experiment was performed with 60 mice (n = 20 in each treatment group). Mice were implanted at Week 0, and five mice from each group were sacrificed at weekly intervals over the next 4 weeks. Blood was collected by intracardiac puncture, and the number of circulating EPCs was assessed via the EPC culture assay.
In the second experiment, 60 mice (n = 20 in each treatment group) were implanted at Week -1, HLI was induced at week 0, and five mice from each group were sacrificed at weekly intervals over the next 4 weeks. At sacrifice, all ischemic, nonnecrotic tissue was collected and stained with fluorescent CD31 antibodies to assess capillary density; blood was collected by intracardiac puncture, and the number of circulating EPCs was assessed via the EPC culture assay. Functional recovery was evaluated from Laser Doppler Perfusion Imaging (LDPI) measurements taken before HLI surgery and at sacrifice, and limb necrosis was assessed visually as previously described. 23 For the third experiment, 42 mice underwent bone marrow transplantation surgery at Week -5, and the bone marrow was allowed to regenerate over 4 weeks. Surviving mice (n = 14 in each treatment group) were implanted at Week -1, HLI surgery was performed at Week 0, and mice were sacrificed at Week 1 and Week 4. After sacrifice, all ischemic, non-necrotic tissue was collected and stained for expression of β-galactosidase (a specific marker for cells derived from donor bone marrow) and CD31 (a specific marker for endothelial cells) to identify bone marrow-derived EPCs at the sites of neovascularization.
EPC culture assay
Total mononuclear cells were isolated from 1 ml of arterial blood by density gradient centrifugation using a Histopaque-1083 (Sigma-Aldrich Inc., St Louis, MO, USA), then cultured in phenol redfree endothelial cell basal medium (Clonetics Corp., San Diego, CA, USA) supplemented with 5% fetal bovine serum, antibiotics, and growth factors on four-well glass slides coated with rat plasma vitronectin (Sigma-Aldrich Inc.) in 0.5% gelatin solution. After 4 days, EPCs were recognized as attached spindle-shaped cells and assayed by costaining with acetylated LDL-DiI (Biomedical Technologies, Stoughton, MA, USA) and FITC-conjugated Bandeiraea simplicifolia lectin I (Vector Laboratories, Burlingame, CA, USA). Fifteen randomly selected fields on each slide were viewed with fluorescence microscopy at 20× magnification, and double-positive cells were identified as EPCs 24 and counted; EPC counts were presented as the average number of EPCs/mm 2 .
Perfusion
Perfusion in both ischemic (left) and non-ischemic (right) limbs was quantified via LDPI (Moor Instruments Inc, Wilmington, DE, USA) before HLI surgery and at predetermined time points afterward. Three consecutive measurements were obtained over the affected region (leg and foot) for each time point. Color-coded images were recorded, and the average perfusion in each (i.e. ischemic and non-ischemic) foot was calculated. To account for variations in ambient light, temperature, and other conditions, perfusion was presented as the ratio of ischemic (left) to non-ischemic (right) measurements.
Capillary density
Tissue samples were mounted and stained for CD31 expression, and one slide for each mouse was examined with light microscopy at 20× magnification. Capillaries positively stained for CD31 (an endothelial cell-specific marker) were counted in five randomly chosen microscopic fields on each slide, and capillary density was presented as the average number of capillaries/mm 2 .
Bone marrow-derived cells Tissue samples from WT mice transplanted with bone marrow from transgenic donors were mounted and stained for both β-galactosidase and CD31 expression. Two slides for each mouse were viewed under fluorescent microscopy at 20× magnification. Five randomly chosen fields were examined for each slide, and cells that were positively stained for both markers were identified and counted; counts were presented as the average number of doublepositive cells/mm 2 .
Statistics
Results are reported as mean ± standard error of the mean (SEM), and statistical analyses were performed with SPSS 12.0 for Windows. Comparisons between groups were analyzed via ANOVA with Dunnett's correction, and a p-value of less than 0.05 was considered significant.
Results
Circulating EPC counts
Within the low-and high-dose E2 treatment groups, mice with HLI displayed significantly greater EPC counts at all weeks than those measured in mice that did not undergo HLI surgery (p < 0.05); EPC counts in animals implanted with the high-dose E2 pellet peaked at Week 2 in both the presence and absence of HLI. In the absence of HLI, the number of circulating EPCs at Weeks 1 and 2 was significantly higher in animals treated with the high-dose E2 pellet than in the low-dose (p < 0.05) or placebotreatment groups (p < 0.05) ( Figure 1A ), and the difference between the high-dose group and the placebo group remained significant at Week 3 (p < 0.05); there was no significant difference between EPC counts in the low-dose and placebo groups at any time point. After induction of HLI, EPC counts were significantly greater in mice that had received the high-dose pellet than in placebotreated mice at Week 2 (p < 0.05 versus placebo) and Week 3 (p < 0.01 for high-dose and p < 0.05 for low-dose versus placebo); EPC counts in the highdose animals were greater than those in the low-dose group, but the difference was not statistically significant ( Figure 1B) .
Perfusion and limb necrosis
At 3 and 4 weeks after HLI surgery, high-dose E2 treatment was associated with significantly greater restoration of perfusion than was observed in animals implanted with either the low-dose E2 or placebo pellets ( Figure 2B ). The ratio of perfusion in the ischemic and non-ischemic limbs was 0.82 ± 0.03 in Week 3 and 0.88 ± 0.11 in Week 4 among animals that received the high-dose E2 pellet, compared to 0.44 ± 0.03 (p < 0.01) and 0.47 ± 0.01 (p < 0.05), respectively, in animals that received the placebo pellet. The differences between lowdose E2 and placebo treatment were not significant at any time point. High-dose E2 treatment was also associated with a lower proportion of limb necrosis at Week 4 (0%) than was observed in animals implanted with the placebo pellet (50%); limb necrosis in the low-dose E2 group was 22%.
Capillary density
At 2, 3 and 4 weeks after induction of HLI, capillary density was significantly higher (p < 0.05) in mice treated with a high dose of E2 than in animals implanted with the placebo pellet (Figure 3) , and the differences between the high-dose and low-dose E2 treatment groups at Weeks 2 and 4 were also significant (p < 0.05).
Bone marrow-derived cells
At 1 and 4 weeks after induction of HLI in mice that had undergone bone marrow transplantation surgery, animals implanted with the high-dose E2 pellet displayed significantly more β-galactosidase-positive (i.e. bone marrow-derived) cells at the site of ischemia than were observed in either the low-dose group or placebo-treated animals ( Figure 4A) ; the difference between the low-dose E2 and placebo-treatment groups was significant at Week 1. The number of β-galactosidase-positive cells at the site of ischemia declined between Weeks 1 and 4 in all treatment groups.
Cells that stained positive for both β-galactosidase and CD31 (representative of bone marrowderived capillary density) were significantly more common 1 week after induction of HLI in mice treated with a high dose of E2 than in low-dose E2 or placebo-treated animals, but this difference abated by Week 4, when the prevalence of doublepositive cells was less than 25 cells/mm 2 in all groups Week -1, and hind-limb ischemia was induced at Week 0. Tissue samples were obtained from mice sacrificed 1-4 weeks later and stained for expression of CD31 (an endothelial cell-specific marker). *p < 0.05 versus the low-dose group, ‡p < 0.05 versus the placebo group.
( Figure 4B ). The prevalence of double-positive cells did not differ significantly between the low-dose E2 and placebo groups.
Discussion
Peripheral artery disease affects 8-12 million people in the United States. 25, 26 The prevalence of peripheral artery disease is lower in premenopausal women than in men, 27 and one factor believed to contribute to this difference is hormonal status. The potential protective role of E2 in peripheral and cardiovascular disease is implied by results in animal models and findings from extensive observational human studies. [28] [29] [30] Administration of E2 yields profound effects in both ischemiareperfusion and chronic heart failure models, 31, 32 and high doses of E2 attenuated the development of heart failure in a rat model of myocardial infarction. 33, 34 The acute protective effects of E2 Figure 4 Incorporation of bone marrow-derived endothelial cells at the sites of neovascularization in mice implanted with pellets containing 1.7 mg estradiol (high dose), 0.39 mg estradiol (low dose), or placebo. Mice underwent transplantation surgery at Week -5, were implanted at Week -1, and hind-limb ischemia was induced at Week 0. Tissue samples were obtained from mice sacrificed 1 and 4 weeks later and stained for expression of CD31 (an endothelial cellspecific marker) and β-galactosidase (a specific marker for cells derived from donor bone marrow). treatment likely evolve, at least in part, through the inhibition of apoptosis. 21, 35 To date, only female animals have been used in animal-model investigations of the potential beneficial effects of E2 for peripheral arterial disease, so we sought to extend these studies to male animals by administering E2 to male mice with HLI. Surgical induction of HLI is a common and reliable method for modeling peripheral arterial disease, [36] [37] [38] [39] [40] and because ischemia occurs in the limb, rather than in the heart, functional recovery can be easily monitored by using LDPI to measure blood flow. Functional data is much more difficult to obtain in models of cardiovascular diseases such as myocardial ischemia-reperfusion injury.
Our results indicate that the beneficial effects of E2 administration observed in female animals with HLI are reproducible in males. Four weeks after HLI surgery, mice administered high doses of E2 had recovered nearly 90% of non-ischemic perfusion and displayed no necrosis, compared to 47% recovery and 50% necrosis in placebo-treated animals; capillary density was also greater with high-dose E2 treatment than with placebo. Furthermore, the effects appeared to be mediated by EPCs; E2 administration dose-dependently mobilized EPCs from the bone marrow, and the mobilized EPCs participated in neovascularization. The prevalence of bone marrow-derived cells in the ischemic region was greater in animals that received the high-dose E2 pellet than in the placebo group at Weeks 1 and 4, and cells expressing both β-galactosidase and CD31 were more common in the high-dose group at Week 1. The difference in double-positive cell prevalence abated by Week 4 because the activity of β-galactosidase decreased over time.
The involvement of EPCs in angiogenesis has been a popular topic of research, and many studies indicate that strategies involving the use of EPCs for therapeutic angiogenesis are feasible. Many growth factors, cytokines, and hormones can influence EPC mobilization and homing, 41 including vascular endothelial growth factor, 4,24,42-44 stromal cell-derived factor 1, 45 statins, 46 and erythropoietin, [47] [48] [49] and the therapeutic potential of these agents for enhancing EPCmediated angiogenesis is being evaluated. The effects of E2 are dependent on EPC incorporation into the sites of neovascularization and are mediated by endothelial nitric oxide synthase, 5 and matrix metalloproteinase-9. 12 Estradiol also reduces myocyte apoptosis in vivo and in vitro via estrogen receptor-and phospho-inositide-3 kinase/aktdependent pathways. 21, 34 Estrogen receptors α and β have been extensively investigated and are vital for the incorporation of bone marrow-derived EPCs in ischemic tissue; the role of the α receptor appears to be more prominent. 11, 50 We acknowledge that the EPC culture assay does not completely exclude cells of a non-endothelial lineage, and that FACS analysis could provide additional specificity. However, the maximum amount of blood that can be taken from a mouse (1 ml) is not sufficient for both the EPC culture assay and FACS analysis, and this limitation can be overcome only by pooling blood samples from several mice, which would reduce the statistical power of subsequent analyses. The limited amount of blood obtainable from each mouse also precluded the measurement of circulating E2 levels. Finally, the small number of animals (five to seven per treatment group per time point) yielded a large distribution of measurements for each time point, which may have occasionally prevented the differences between treatment groups from reaching statistical significance.
In conclusion, our study shows that E2 dosedependently increases the level of circulating EPCs in the peripheral blood of both intact male mice and male mice with HLI, and that E2-mobilized EPCs home to the foci of neovascularization during HLI to promote recovery. Furthermore, E2 was also associated with improved blood-flow recovery, greater capillary density, and less limb necrosis, with optimal effects observed 2-3 weeks after the onset of HLI. These findings suggest that systemic E2 administration may increase EPC-mediated neovascularization under ischemic conditions caused by peripheral artery disease.
